US Health Secretary Kennedy opens access to some unapproved peptides The request covers all six peptides mentioned: BPC-157 TB-500 Epitalon KPV MOTS-c Semax https://public-inspection.federalregister.gov/2026-22192.pdf - React -

Has anyone had any issues with hair loss with KLOW? My wife has been taking it for about 9 weeks now and she noticed her hair was thinning. There’s some new growth but not a lot. Any advice or insight would be appreciated!

Peptide Protocols Are Now Posted I’ve added peptide protocol-style recommendations inside the community to help give everyone a better general understanding of different compounds, stacks, timing concepts, and research-based approaches. Quick reminder: Everything posted is for research use only. These are recommendations and educational examples only. Nothing is set in stone, and none of this should be taken as medical advice, a required protocol, or a one-size-fits-all plan. The goal is simple: Help you better understand the compounds, how they’re commonly discussed in research settings, and how different peptides may complement each other from an educational standpoint. I’ll keep building this section out over time. Drop a comment below: What peptides are you interested in learning more about that you don’t currently see listed?

Are We Watching Prohibition 2.0 Happen With Peptides? I've been thinking a lot about what's happening in the peptide industry right now, and I genuinely believe we're watching history repeat itself. Think about Prohibition. The government tried to eliminate alcohol, but instead of eliminating demand, they created an underground industry they couldn't effectively regulate or control. Now look at what's happening with peptides. The demand is already here. People are asking questions, doing their own research, and challenging the traditional healthcare system. And I think the government has a much bigger problem on its hands than it realizes. At what point does restricting access stop protecting consumers and start pushing them toward an even more dangerous, unregulated market? In this video, I break down my thoughts on the FDA, pharmaceutical companies, government regulation, and why I believe the peptide industry isn't going anywhere. This is my opinion, and I know not everyone is going to agree with it. But that's exactly why I want to have this conversation. Watch the video and let me know what you think. Should the government focus on restricting peptides or creating a safer, more transparent regulatory framework?

What tesamorelin research actually shows about GHRH signaling, and why the way it was studied shaped its reputation. Tesamorelin gets called 'the visceral fat peptide.' It's catchy, and it's a little misleading. The more interesting story is how the body's growth hormone system works and why this compound was studied the way it was. TWO STEPS, ONE PATHWAY Start with the biology. The hypothalamus releases GHRH, which tells the pituitary to release growth hormone (GH). Ghrelin, a hormone made mainly in the stomach, amplifies that signal. That's one reason the biggest natural GH pulses tend to happen during deep sleep in a fasted state. Step two happens in the liver, which converts GH into IGF-1, the messenger tied to much of GH's downstream activity. Insulin needs to be present for that conversion to work efficiently. So the strongest GH release and the strongest IGF-1 production tend to happen under different conditions. Tesamorelin is a modified GHRH analogue. Researchers study it for how it binds GHRH receptors on pituitary somatotroph cells and prompts the release of endogenous GH. Because it works upstream, it keeps the pulsatile pattern and the normal feedback brakes, like somatostatin, in the picture. SO WHY THE FAT REPUTATION? Not because it has a special fat-seeking receptor. It acts on the GHRH pathway, the same one other GHRH-pathway compounds use. The reputation comes from what was measured: the large human trials used CT scans to track visceral adipose tissue. In randomized, double-blind, placebo-controlled trials in people with HIV-associated abdominal fat accumulation, visceral fat fell about 15.2% over 26 weeks, versus a rise of about 5.0% on placebo (Falutz et al., NEJM, 2007). A 2026 meta-analysis of five randomized trials reported an average reduction of 27.71 cm² in visceral adipose tissue. No published head-to-head trial compares tesamorelin with other GHRH-pathway compounds. The difference is the evidence base, not proof of a unique mechanism.